Trepipam (; developmental code name SCH-12679) is a dopamine receptor agonist of the benzazepine group that was never marketed. It acts specifically as an agonist of the dopamine D<sub>1</sub> receptor. It is closed related structurally to fenoldopam, a peripherally acting selective D<sub>1</sub> receptor partial agonist which is used as an antihypertensive agent.